Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|April 11, 2008
Cubist Pharmaceuticals finds contaminant 2-mercaptobenzothiazole (MBT) in Cubicin infusion pumps
Cubist Pharmaceuticals finds impurity in reconstituted daptomycin
Advertisement
Cubist Pharmaceuticals is
Advertisement
Related to this article
Researchers compared vaccine coadministration with single-dose, sequential vaccination for the RSVPreF3 OA vaccine formulation in adults.
A study of women aged 50 to 69 years found that thrombotic risk varied by route of administration, estradiol dose, and duration of use.
Despite technology fostering a new generation of health care delivery, experts believe rural health solutions should be sought elsewhere.
Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled use, a new study finds.
Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.
Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.
Darren Mensch, PharmD, BCPS, BCACP, provides evidence-based nuance regarding the emergence of mRNA vaccine technology and health care’s understanding of it.
Advertisement
Advertisement
Trending on Drug Topics
1
Normal vs. Concerning COVID-19 Vaccine Reactions: A Pharmacist's Guide
2
Pharmacists Are Vital in Complex, Team-Based Treatment of PAD
3
CDC Opens Orders for COVID-19 Vaccines in Vaccines for Children
4
FAQ: Pharmacist Understanding of mRNA Vaccine Technology
5